Systemic Kappa Opioid Receptor Agonists in the Treatment of Chronic Pruritus: A Literature Review

Phan, Ngoc Quan; Lotts, Tobias; Antal, Attila; Bernhard, Jeffrey D.; Ständer, Sonja

doi:10.2340/00015555-1353

Cited by 126 publications

(87 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…101) Thus, opioid μ-and κ-receptors are potential therapeutic targets for pruritus. In the spinal cord, the opioid μ-receptor isoform MoR1d heterodimerizes with the bombesin BB 2 receptor, and the stimulation of MoR1d by morphine produces an effect similar to the stimulation of the BB 2 receptor.…”

Section: Itch-inhibitory Systemmentioning

confidence: 99%

Potential New Therapeutic Targets for Pathological Pruritus

Kuraishi

2013

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Very few approved medications are indicated for the treatment of pruritus, and drug development for pruritic diseases is awaited. During the past two decades, progress has been made in understanding the molecular basis of the physiology and pathophysiology of pruritus. Newly identified potential targets for pathological pruritus include receptors (histamine H 4 receptor, leukotriene B 4 receptors, interleukin-31 receptor A, bombesin BB 2 receptor, toll-like receptor 3, α-adrenoceptor, and opioid μ-and κ-receptors), channels (transient receptor potential (TRP) V3 and TRPA1 channels), and enzymes (histidine decarboxylase, sphingomyelin glucosylceramide deacylase, 5-lipoxygenase, leukotriene A 4 hydrolase, and autotaxin). The development of specific, effective blockers and agonists/antagonists of these targets is awaited.

show abstract

Section: Itch-inhibitory Systemmentioning

confidence: 99%

Potential New Therapeutic Targets for Pathological Pruritus

Kuraishi

2013

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

show abstract

“…It is generally thought that the mu-opioid system induces itch, whereas the kappaopioid system suppresses itch at the central level. 7,67) Recently, the effectiveness of nalfurafine hydrochloride (reMItcH ® ), a selective kappa-opioid receptor agonist, on hemodialysis-related uremic pruritus was validated in a Phase III, randomized double-blind placebo-controlled trial. 68) This drug is also expected to make further contributions to the treatment of patients with intractable itch, such as those with cholestasis and atopic dermatitis.…”

Section: New Anti-pruritic Drugsmentioning

confidence: 99%

An Update on Peripheral Mechanisms and Treatments of Itch

Tominaga

Takamori

2013

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Histamine H 1 -receptor blockers are used to treat all types of itch resulting from serious skin diseases such as atopic dermatitis, as well as from renal and liver diseases. However, they often lack efficacy in chronic itch, a profound clinical problem that decreases quality of life. The development of effective treatments requires a full understanding of the fundamental mechanisms of itch. Recent studies have indicated that the pathogenic mechanisms of itch also involve agonists other than histamine, including proteases, neuropeptides, cytokines, and opioids, as well as their cognate receptors. Release of these pruritogenic mediators and modulators into the periphery may directly activate itch-mediating C-fibers via specific receptors on the nerve terminals. Histological observations have shown increased epidermal nerve densities in patients with atopic dermatitis, suggesting that the higher density is at least partly responsible for itch sensitization. This

show abstract

“…for 24 h), naltrexone (50-100 mg/day orally) or nalmefene (20-120 mg/day orally) may show considerable relief of itch (48). Butorphanol is a κ-opioid agonist and a μ-antagonist and possess (weak) analgesic and antipruritic effects in non-Hodgkin lymphoma when given at a dose of intranasally 1 mg/day (49,50).…”

Section: Diagnostics and Treatmentmentioning

confidence: 98%

Paraneoplastic Itch: An Expert Position Statement from the Special Interest Group (SIG) of the International Forum on the Study of Itch (IFSI)

Weißhaar¹,

Weiß²,

Mettang³

et al. 2015

Acta Derm Venerol

View full text Add to dashboard Cite

In clinical practice, the term "paraneoplastic itch" is used to describe itch in patients with cancer. Patients with hematological or solid tumor malignancies can be affected. In general, paraneoplastic itch is considered a rare disorder. However, paraneoplastic itch in hematological malignancies such as polycythemia vera and lymphoma are relatively frequent while other forms of paraneoplastic itch are in fact extremely rare. The true frequency of this symptom is unclear, epidemiological data in this field are limited. Itch in malignant disease may additionally impair patients' quality of life. A population-based cohort study showed that chronic itch without concomitant skin changes is a risk factor for having undiagnosed hematologic and bile duct malignancies. Paraneoplastic itch is rather resistant to treatment. In 2012, an interdisciplinary interest group of physicians and researchers was founded, aiming to generate a clear definition of paraneoplastic itch. In this paper we briefly review the current knowledge and aim to define what can be summarized under the term "paraneoplastic itch".

show abstract

Systemic Kappa Opioid Receptor Agonists in the Treatment of Chronic Pruritus: A Literature Review

Cited by 126 publications

References 67 publications

Potential New Therapeutic Targets for Pathological Pruritus

Potential New Therapeutic Targets for Pathological Pruritus

An Update on Peripheral Mechanisms and Treatments of Itch

Paraneoplastic Itch: An Expert Position Statement from the Special Interest Group (SIG) of the International Forum on the Study of Itch (IFSI)

Contact Info

Product

Resources

About